Moderna的COVID-19疫苗在早期试验中表现良好

Moderna公司的Covid-19疫苗在最初的安全试验中，测试的所有患者均成功产生了抗体，代表着美国的疫苗研究跨过了一个重要的里程碑。然而，一些患者在试验中出现了副作用，部分较严重。该疫苗将在本月晚些时候进行更大规模的后期试验，很可能决定它是否被美国监管机构批准。早期试验中分三个剂量类型给患者注入疫苗，其中中间剂量组里有超过一半的人出现轻度到重度疲劳、寒战、头疼和肌肉疼痛的症状；有40%的人在第二次接种后出现发烧。而在给予最高剂量的14名患者中，有3名患者出现了严重的副作用，但最高剂量并没有在更大规模的试验中使用。杜克人类疫苗研究所的医生和研究员托尼-穆迪说，对于一种疫苗来说，有这样的副作用发生率是 "不寻常 "的。从好的方面看，他说，产生的抗体水平 "真的令人鼓舞"。早期试验成功后，Moderna的股价在收市后的交易中上涨了13.3%。由于希望其疫苗能够迅速获得批准，该股今年的价值已经增长了三倍多。

Moderna Inc.’s Covid-19 vaccine produced antibodies to the coronavirus in all patients tested in an initial safety trial, federal researchers said, clearing an important milestone as the U.S. continues to grapple with a surge in new infections. The findings are likely to increase hopes that a vaccine can be brought to market quickly. However, a number of patients in the trial experienced side effects, some of them severe. The vaccine will move into a much larger late-stage trial later this month that’s likely to determine whether it’s approved by U.S. regulators. Moderna’s shares gained 13.3% in trading after the market closed. The stock has more than tripled in value this year on hopes that its vaccine will gain rapid approval. More than half of those who got the middle of three doses suffered mild to moderate fatigue, chills, headache and muscle pain. Also, 40% of people in the middle-dose group experienced a fever after the second vaccination. Three of 14 patients given the highest dose experienced severe side effects, but that dose is not being used in larger trials. “Man, that is a lot of adverse events,” said Tony Moody, a doctor and researcher at the Duke Human Vaccine Institute. He said it would be “unusual” for a vaccine to have this rate of side effects. On the plus side, he said that the antibody levels produced were “really encouraging.”  source

指尖新闻：高信噪比，一目了然

新冠疫情追踪